TY - JOUR
T1 - Novel targets and future strategies for acute cardioprotection
T2 - Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart
AU - J. Hausenloy, Derek
AU - Garcia-Dorado, David
AU - Bøtker, Hans Erik
AU - M. Davidson, Sean
AU - Downey, James
AU - B. Engel, Felix
AU - Jennings, Robert
AU - Lecour, Sandrine
AU - Leor, Jonathan
AU - Madonna, Rosalinda
AU - Ovize, Michel
AU - Perrino, Cinzia
AU - Prunier, Fabrice
AU - Schulz, Rainer
AU - Sluijter, Joost P.G.
AU - Van Laake, Linda W.
AU - Vinten-Johansen, Jakob
AU - M. Yellon, Derek
AU - Ytrehus, Kirsti
AU - Heusch, Gerd
AU - Ferdinandy, Péter
N1 - Funding Information:
D.J.H. was funded by the British Heart Foundation (grant number FS/10/039/28270), the Rosetrees Trust, and is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. D.G.-D. is supported by the Spanish Institute of Health, Instituto de Salud Carlos III (grants PIE 13/00027, RETICS-RIC,RD12/0042/0021, and PI14/01431). C.P. was funded by the Italian Ministry of Health (grant number: GR-2009-1596220) and by the Italian Ministry of University (grant number: RBFR124FEN). L.V.L. was supported by the Netherlands Heart Foundation (Dekker 2013T056) and European Society of Cardiology Research Grant 2016. K.Y. has been supported by the Norwegian Council on Cardiovascular Diseases, Norway. G.H. was supported by the German Research Foundation (He 1320/18-3 and SFB 1116/B8). P.F. and R.S. were funded by the European Foundation for the Study of Diabetes (EFSD) New Horizons Collaborative Research Initiative from the European Association for the Study of Diabetes (EASD) and by the European Cooperation in Science and Technology (COST EU-ROS). P.F. was funded by the National Research Development and Innovation Office of Hungary (OTKA K 109737, OTKA ANN 107803, NVKP 16-1-2016-0017).
Publisher Copyright:
© 2017 The Author.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Ischaemic heart disease and the heart failure that often results, remain the leading causes of death and disability in Europe and worldwide. As such, in order to prevent heart failure and improve clinical outcomes in patients presenting with an acute ST-segment elevation myocardial infarction and patients undergoing coronary artery bypass graft surgery, novel therapies are required to protect the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI). During the last three decades, a wide variety of ischaemic conditioning strategies and pharmacological treatments have been tested in the clinic - however, their translation from experimental to clinical studies for improving patient outcomes has been both challenging and disappointing. Therefore, in this Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart, we critically analyse the current state of ischaemic conditioning in both the experimental and clinical settings, provide recommendations for improving its translation into the clinical setting, and highlight novel therapeutic targets and new treatment strategies for reducing acute myocardial IRI.
AB - Ischaemic heart disease and the heart failure that often results, remain the leading causes of death and disability in Europe and worldwide. As such, in order to prevent heart failure and improve clinical outcomes in patients presenting with an acute ST-segment elevation myocardial infarction and patients undergoing coronary artery bypass graft surgery, novel therapies are required to protect the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI). During the last three decades, a wide variety of ischaemic conditioning strategies and pharmacological treatments have been tested in the clinic - however, their translation from experimental to clinical studies for improving patient outcomes has been both challenging and disappointing. Therefore, in this Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart, we critically analyse the current state of ischaemic conditioning in both the experimental and clinical settings, provide recommendations for improving its translation into the clinical setting, and highlight novel therapeutic targets and new treatment strategies for reducing acute myocardial IRI.
KW - Cardioprotection
KW - Ischaemia
KW - Ischaemic conditioning
KW - Myocardial Infarction
KW - Reperfusion
UR - http://www.scopus.com/inward/record.url?scp=85016601630&partnerID=8YFLogxK
U2 - 10.1093/cvr/cvx049
DO - 10.1093/cvr/cvx049
M3 - Review article
C2 - 28453734
AN - SCOPUS:85016601630
SN - 0008-6363
VL - 113
SP - 564
EP - 585
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 6
ER -